Reduce Oncology Trial Delays from Study Start-Up to Patient Recruitment
About this webinar
Complex oncology trials put pressure on every stage of study execution, from selecting and preparing the right sites to finding eligible patients in increasingly specific populations.
What can sponsors and CROs do to reduce avoidable delays and make recruitment more predictable? In this webinar, the featured speakers will explore how early site engagement and stronger feasibility can improve site selection, uncover operational barriers sooner and support successful enrollment across early- and late-phase oncology studies.
As oncology trials become more biomarker-driven and patient populations harder to identify, effective pre-screening and patient identification are becoming increasingly important. The discussion will examine approaches for finding patients with specific genetic mutations and consider how referral pathways and site capabilities influence recruitment.
Patient recruitment requirements can also differ significantly across phases of development. The webinar will explore how patient identification, referral pathways and site capabilities can vary between Phase I and later-phase studies, helping sponsors and CROs consider these differences when planning recruitment strategies. The discussion will also compare the practical realities of running oncology trials across the US and Europe.
Register for this webinar to learn how patient recruitment strategies can improve patient identification, site readiness and enrollment across complex oncology trials.
Who should attend
This webinar will appeal to:
- Biotech and Pharmaceutical leaders developing oncology programs and assets
- Clinical Development teams planning early- and late-phase oncology studies
- Clinical Operations leaders and teams responsible for study execution, recruitment and enrollment
- CRO professionals supporting oncology trial planning and delivery
- Study Start-Up and Site Activation teams looking to improve site readiness and reduce activation timelines
- Feasibility and Site Selection teams evaluating research sites for complex oncology studies
- Patient Recruitment and Enrollment teams focused on patient identification, pre-screening and reducing screening failures
- Translational and Biomarker Strategy teams working with biomarker-driven patient populations
- Program and Portfolio Managers evaluating clinical readiness, site capabilities and operational feasibility
- CEOs, Chief Development Officers (CDOs) and Biotech Founders seeking practical insights into executing complex oncology programs
What you will learn
Attendees will gain insight into:
- How early site involvement can strengthen feasibility, improve site selection and identify operational barriers before they affect timelines
- Practical approaches to pre-screening and patient identification for complex, biomarker-driven trials
- How patient identification, referral pathways and site capabilities differ between Phase I and later-phase oncology studies
Featured Speakers
Chloe Rose, PhD
Chloe Rose is Vice President, Site Solutions at Pratia. She joined Pratia in 2021, bringing extensive experience in clinical research and global pharmaceutical operations.
Chloe began her career as a European Clinical Trial Manager at a global pharmaceutical company before moving into Global Trial Management. She was later selected to lead a newly established Strategy and Operations department, where she played a key role in integrating new business acquisitions and implementing strategic initiatives to strengthen operational efficiency.
Throughout her professional experience, Chloe has focused on improving clinical trial delivery and accelerating access to innovative medicines for patients.
She holds a PhD in Bioengineering and a BSc in Pharmacology from the University of Southampton in the UK.
Julio Peguero, MD
Dr. Julio A. Peguero is a Medical Oncologist and Medical Director of Research at Oncology Consultants in Houston, Texas. He has served as a Principal Investigator on more than 200 clinical trials, including first-in-human studies, with extensive experience in early-phase oncology research and precision medicine.
Dr. Peguero earned his Medical Degree from Universidad Autónoma de Guadalajara and completed his Internal Medicine residency at the University of Texas Dell Medical School. He completed his Medical Oncology fellowship in 2013 through the University of Texas Medical Branch at Galveston and University of Texas MD Anderson Cancer Center, with training in Phase I research.
Since joining Oncology Consultants in 2013, Dr. Peguero has led a competitive clinical research program and contributed to research presented at ASCO, ESMO, ASH and AACR, with publications in Journal of Clinical Oncology, The Lancet Oncology and Blood.
He also serves as Chair of the Phase I Committee at Exigent Research Network.
Santiago Viteri, MD, PhD
Dr. Santiago Viteri is a Medical Oncologist with a degree in Medicine and specialist training from the University of Navarra. He has extensive experience in cancer molecular biology, personalized medicine, thoracic tumors and clinical research.
He began his career at Mateu Orfila Hospital in Menorca, where he treated patients across a broad range of tumor types. He later spent 13 years at the Dr. Rosell Oncology Institute, initially as a Staff Physician before taking on leadership responsibilities and becoming Clinical Director. In this role, he led a team of 14 oncologists providing care across four hospitals in the Barcelona area.
Dr. Viteri has also contributed to medical education, training specialists from Latin America and Europe and speaking at national and international conferences.
In 2021, he co-founded Mi Cancer Center SLP, an independent cancer care initiative focused on comprehensive, personalized care for patients and their families. He is now part of the team developing UOMI Cancer Center in Barcelona and Lleida. He also heads Pratia Sirius – a joint venture between Pratia and UOMI.
Lauren Stockwell
Lauren is a passionate and driven clinical research professional. As the Associate Director of Education & Engagement for the Society for Clinical Research Sites (SCRS), she works tirelessly to develop educational and mentorship programming that supports the industry holistically. This includes her work with the SCRS Oncology Program, striving to empower clinical research sites as essential partners in the cancer research ecosystem. Through this work, she helps ensure that oncology-focused sites, including those newer to the space, have the tools, connections, and pathways they need to grow and thrive.
SCRS is the leading advocacy organization dedicated to unifying the voice of the global clinical research site community. Representing more than 12,000+ sites in 65 countries, SCRS facilitates industry collaborations and conversations dedicated to site-focused advocacy, education, mentorship, and connection.
Throughout her career, Lauren has had the pleasure of leading various organizations and teams and is committed to being a change-maker within the industry through honest and intentional collaboration.
Partner for this event
Pratia
Pratia, a research site network and part of the Humaneva Group Inc., leads global clinical research and expands patient access to innovative treatments. As the largest site network in Europe and the world’s leading oncology research network, Pratia operates 100+ research sites across eight countries, including the U.S. and Türkiye, covering 85% of all therapeutic areas and executing 600+ active clinical trials annually. Pratia’s strategy relies on three pillars: establishing accessible sites for patients, adapting operations to local healthcare systems, and leveraging advanced study digitization with proprietary software like Hyggio for efficient, reliable data delivery.